To date, there are no standardized recommendations for management of thrombotic microangiopathy (TMA), a potentially life-threatening toxicity, in patients treated with antivascular endothelial growth factor (VEGF) agents.
In this pilot prospective cohort, we have assigned 17 patients with various solid tumor types who developed a biopsy-proven renal TMA to receive, in an unblinded fashion, either intensive (group 1, 10 patients) [maximally tolerated antihypertensive treatment + corticosteroid (0.5 to 1 mg/kg/day for 4 weeks followed by rapid tapering) + fresh plasma perfusion (15 ml/kg/day for 10 days) +/2 plasma exchange for 10 days] or conservative (group 2, 6 patients) [maximally tolerated antihypertensive treatment alone ( ‡ 3 drugs including angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker to achieve As shown in Table 1 , there was no significant difference between groups with respect to patient characteristics, TMA biological and renal parameters' at baseline. Histologically, all patients showed purely glomerular TMA. Conservative treatment patients' presented more focal and segmental sclerotic lesions. Of note in both patient groups, similar minimal tubulointerstitial lesions were noted.
While not statistically significant, glomerular filtration rate (GFR) decreased from 64.5 to 58.8 ml/min/1.73m 2 in the intensive group. This GFR decrease was constantly noted even after omission of the three patients with baseline creatinine levels ‡ 1.5 mg/dl in this group. In these same patients, serum creatinine progressed as follows: 1.5, 1.53 and 2.5 mg/dl to 1.65, 2.1 and 2.5 mg/dl, respectively. In contrast, GFR improved from 62 to 65.1 ml/min/1.73m 2 in the conservative group. Systolic and diastolic blood pressure, as well as proteinuria levels decreased to a significant extent both in the intensive and in the conservative groups but more in the former group. On the other hand, treatment-related serious adverse events were reported in two patients (one steroid-induced diabetes mellitus and one meningococcal meningitis in a predisposed chronic sinusitis patient), both belonging to the intensive group. However, only the intensive treatment group has shown improvement of hematological parameters (hemoglobin, platelet and lacticodeshydrogenase).
Though this is demonstrated in a relatively small cohort, without randomization, conservative treatment was safe and associated with a significant reduction in blood pressure, proteinuria and without decrease in renal function. Although the results might not be applicable on patients with severe renal damage from TMA, these pilot data plead for a full-fledged clinical trial, testing whether conservative treatment may be beneficial in TMA with or without continuing anti-VEGF therapy [1] .
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